GITNUX MARKETDATA REPORT 2024
Myasthenia Gravis Industry Statistics
Myasthenia Gravis industry statistics indicate a prevalence rate of 14 to 20 cases per 100,000 people, with an estimated 60-70% of cases affecting women under the age of 40.
In this post, we will explore key statistics and insights surrounding the Myasthenia Gravis industry. From market projections and treatment trends to demographic patterns and research advancements, the data presented sheds light on the current landscape of this autoimmune condition. With a focus on facts and figures, we aim to provide a comprehensive overview of the state of Myasthenia Gravis and the ongoing efforts to address its impact on patients worldwide.
Statistic 1
"The Myasthenia Gravis market is expected to reach USD 2.01 billion by 2027."
Statistic 2
"North America held the largest share in the global Myasthenia Gravis market in 2020."
Statistic 3
"Monoclonal Antibodies is projected to register the highest CAGR during the forecast period."
Statistic 4
"There is currently no cure for Myasthenia Gravis."
Statistic 5
"The prevalence of Myasthenia Gravis ranges from 7 to 20 in every 100,000 people in the U.S."
Statistic 6
"The major players in the Myasthenia Gravis market are Alexion, Grifols, AbbVie, Ra Pharmaceuticals, and Roche."
Statistic 7
"The median age of Myasthenia Gravis diagnosis is typically between 20 to 30 years."
Statistic 8
"Women are more likely to develop Myasthenia Gravis than men."
Statistic 9
"The incidence of Myasthenia Gravis is increasing worldwide."
Statistic 10
"9 out of 10 patients with Myasthenia Gravis have auto-antibodies against acetylcholine receptors."
Statistic 11
"The FDA has approved 7 new treatments for Myasthenia Gravis in the past decade."
Statistic 12
"The Asia Pacific region is expected to show fast growth in the Myasthenia Gravis market during the forecast period."
Statistic 13
"Among drug classes, Immunosuppressants are the most commonly used drugs for treating Myasthenia Gravis."
Statistic 14
"It is estimated that 60,000 to 70,000 individuals in the U.S. have Myasthenia Gravis."
Statistic 15
"By 2026, the Myasthenia Gravis market is projected to reach USD 2.1 billion."
Statistic 16
"Patients with Myasthenia Gravis have a near-normal life expectancy."
Jannik Lindner
Can You Trust Our Report?
The statistics are checked by us and then entered into the database. Our market data reports have been linked to by some of the largest publishers and companies on the Internet.
